IL293469B2 - Compounds for treatment of eye diseases associated with excessive vascularisation - Google Patents
Compounds for treatment of eye diseases associated with excessive vascularisationInfo
- Publication number
- IL293469B2 IL293469B2 IL293469A IL29346922A IL293469B2 IL 293469 B2 IL293469 B2 IL 293469B2 IL 293469 A IL293469 A IL 293469A IL 29346922 A IL29346922 A IL 29346922A IL 293469 B2 IL293469 B2 IL 293469B2
- Authority
- IL
- Israel
- Prior art keywords
- composition
- eye
- chloro
- methyl
- neovascularisation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19218062 | 2019-12-19 | ||
| EP20156158 | 2020-02-07 | ||
| PCT/EP2020/086993 WO2021123142A1 (en) | 2019-12-19 | 2020-12-18 | Compounds for treatment of eye diseases associated with excessive vascularisation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL293469A IL293469A (en) | 2022-08-01 |
| IL293469B1 IL293469B1 (en) | 2023-12-01 |
| IL293469B2 true IL293469B2 (en) | 2024-04-01 |
Family
ID=74141502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL293469A IL293469B2 (en) | 2019-12-19 | 2020-12-18 | Compounds for treatment of eye diseases associated with excessive vascularisation |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11478465B2 (https=) |
| EP (2) | EP3886858B1 (https=) |
| JP (1) | JP7730816B2 (https=) |
| KR (1) | KR20220118419A (https=) |
| CN (1) | CN114845718B (https=) |
| AU (1) | AU2020408179B2 (https=) |
| BR (1) | BR112022009192A2 (https=) |
| CA (1) | CA3157394A1 (https=) |
| DK (1) | DK3886858T3 (https=) |
| ES (1) | ES2921360T3 (https=) |
| IL (1) | IL293469B2 (https=) |
| MX (1) | MX2022006439A (https=) |
| PL (1) | PL3886858T3 (https=) |
| WO (1) | WO2021123142A1 (https=) |
| ZA (1) | ZA202204939B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| KR20220118419A (ko) * | 2019-12-19 | 2022-08-25 | 액티브 바이오테크 에이비 | 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물 |
| PL4312986T3 (pl) | 2021-04-01 | 2025-02-17 | Active Biotech Ab | Preparat lakwinimodu do stosowania do oczu |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| AU2024306742A1 (en) * | 2023-06-28 | 2025-12-04 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of mpn |
| CN117256554A (zh) * | 2023-09-08 | 2023-12-22 | 益诺思生物技术南通有限公司 | 一种c57bl/6j小鼠新生血管型眼病模型及其构建方法 |
| KR102925647B1 (ko) * | 2023-10-13 | 2026-02-11 | 재단법인 대구경북첨단의료산업진흥재단 | 안질환 치료제 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
| WO2010070449A2 (en) | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| WO2012006538A1 (en) * | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| IN2014MN00333A (https=) | 2011-07-28 | 2015-09-25 | Teva Pharma | |
| US20150111833A1 (en) * | 2012-04-20 | 2015-04-23 | Howard University | Method Of Treating An Ocular Disease And Compositions Effective For Treating An Ocular Disease |
| EP2849762A4 (en) | 2012-05-16 | 2016-02-24 | Aadigen Llc | MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY DISORDERS |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| MX373894B (es) * | 2012-11-08 | 2020-07-09 | Clearside Biomedical Inc | Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| CN109432073A (zh) | 2013-01-08 | 2019-03-08 | 帕萨罗杰卡有限公司 | Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途 |
| EP3019526A1 (en) * | 2013-07-11 | 2016-05-18 | Novartis AG | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
| WO2015060812A1 (en) | 2013-10-21 | 2015-04-30 | Howard University | Treating ocular disease with efflux transporter inhibitors |
| EP3068395A4 (en) | 2013-11-15 | 2017-07-12 | Teva Pharmaceutical Industries Ltd. | Treatment of glaucoma using laquinimod |
| CA2933900A1 (en) * | 2013-12-20 | 2015-06-25 | Georgia Tech Research Corporation | Formulations and methods for targeted ocular delivery of therapeutic agents |
| WO2017120355A1 (en) | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
| CA3010862A1 (en) | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
| JP2020528082A (ja) * | 2017-07-17 | 2020-09-17 | ロイズマン，キース | 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達 |
| MX2020006460A (es) | 2017-12-22 | 2020-11-06 | Chemocentryx Inc | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. |
| WO2019126424A1 (en) | 2017-12-22 | 2019-06-27 | Chemocentryx, Inc. | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| BR112020019822A2 (pt) | 2018-04-02 | 2021-03-16 | Chemocentryx, Inc. | Profármacos de antagonistas bicíclicos fundidos de c5ar |
| KR20220118419A (ko) * | 2019-12-19 | 2022-08-25 | 액티브 바이오테크 에이비 | 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물 |
-
2020
- 2020-12-18 KR KR1020227019983A patent/KR20220118419A/ko active Pending
- 2020-12-18 MX MX2022006439A patent/MX2022006439A/es unknown
- 2020-12-18 ES ES20838435T patent/ES2921360T3/es active Active
- 2020-12-18 AU AU2020408179A patent/AU2020408179B2/en active Active
- 2020-12-18 EP EP20838435.4A patent/EP3886858B1/en active Active
- 2020-12-18 WO PCT/EP2020/086993 patent/WO2021123142A1/en not_active Ceased
- 2020-12-18 IL IL293469A patent/IL293469B2/en unknown
- 2020-12-18 CA CA3157394A patent/CA3157394A1/en active Pending
- 2020-12-18 JP JP2022535637A patent/JP7730816B2/ja active Active
- 2020-12-18 DK DK20838435.4T patent/DK3886858T3/da active
- 2020-12-18 CN CN202080087752.XA patent/CN114845718B/zh active Active
- 2020-12-18 EP EP22167643.0A patent/EP4094765A1/en not_active Withdrawn
- 2020-12-18 PL PL20838435.4T patent/PL3886858T3/pl unknown
- 2020-12-18 BR BR112022009192A patent/BR112022009192A2/pt unknown
-
2021
- 2021-07-02 US US17/366,979 patent/US11478465B2/en active Active
-
2022
- 2022-05-05 ZA ZA2022/04939A patent/ZA202204939B/en unknown
- 2022-09-07 US US17/939,109 patent/US12208091B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3886858T3 (pl) | 2022-08-29 |
| EP3886858B1 (en) | 2022-05-11 |
| ZA202204939B (en) | 2023-12-20 |
| US12208091B2 (en) | 2025-01-28 |
| EP4094765A1 (en) | 2022-11-30 |
| DK3886858T3 (da) | 2022-08-22 |
| ES2921360T3 (es) | 2022-08-24 |
| CN114845718A (zh) | 2022-08-02 |
| KR20220118419A (ko) | 2022-08-25 |
| IL293469A (en) | 2022-08-01 |
| CN114845718B (zh) | 2025-05-16 |
| CA3157394A1 (en) | 2021-06-24 |
| MX2022006439A (es) | 2022-07-19 |
| WO2021123142A1 (en) | 2021-06-24 |
| BR112022009192A2 (pt) | 2022-07-26 |
| EP3886858A1 (en) | 2021-10-06 |
| US20230066364A1 (en) | 2023-03-02 |
| US20210322400A1 (en) | 2021-10-21 |
| AU2020408179A1 (en) | 2022-06-30 |
| JP7730816B2 (ja) | 2025-08-28 |
| IL293469B1 (en) | 2023-12-01 |
| JP2023509336A (ja) | 2023-03-08 |
| US11478465B2 (en) | 2022-10-25 |
| AU2020408179B2 (en) | 2025-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12208091B2 (en) | Compounds for treatment of eye diseases associated with excessive vascularisation | |
| AU2023251388B2 (en) | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells | |
| JP6868014B2 (ja) | 翼状片を治療するための組成物及び方法 | |
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| JP2012524073A (ja) | 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用 | |
| KR102307421B1 (ko) | 다중 키나아제 억제제 및 안구 섬유증에의 사용 | |
| Van Bergen et al. | Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery | |
| EP3808352A1 (en) | Use of salidroside and derivative thereof in preparation of inhibitor medicament for diseases of ophthalmic fibrosis caused by abnormalities of extracellular matrix proteins | |
| TW200815416A (en) | Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases | |
| CA2909111A1 (en) | The local treatment of inflammatory ophthalmic diseases | |
| Galor et al. | Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery | |
| Gillies et al. | Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy | |
| HK40061312B (en) | Compounds for treatment of eye diseases associated with excessive vascularisation | |
| HK40061312A (en) | Compounds for treatment of eye diseases associated with excessive vascularisation | |
| EA045318B1 (ru) | Соединения для лечения глазных болезней, связанных с избыточной васкуляризацией | |
| WO2020203822A1 (ja) | 血管新生を伴う網膜疾患の治療又は予防のための併用医薬 | |
| RU2815482C2 (ru) | Лечение глазных болезней типа дегенерации желтого пятна, глаукомы и диабетической ретинопатии с помощью лекарственных средств, устраняющих стареющие клетки | |
| Croasdell | Association for Research in Vision and Ophthalmology (ARVO)-2016 Annual Meeting. Seattle, Washington, USA-April 29-May 5, 2016 |